Revolution Medicines (RVMD)’ daraxonrasib was granted FDA orphan designation as a treatment of pancreatic cancer, according to a post to the agency’s website.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines: Strong Buy Rating Driven by Innovative Oncology Advancements and Strategic Market Position
- Revolution Medicines initiated with an Outperform at Mizuho
- Revolution Medicines rises 8.8%
- Revolution Medicines rises 11.5%
- Revolution Medicines price target raised to $80 from $78 at BofA